Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duolac ATP
- Development stage
- Preclinical
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Duolac ATP is a combination product containing multiple probiotic strains and adenosine triphosphate (ATP), developed by Cell Biotech. It has been investigated by Soonchunhyang University Hospital in a clinical trial (NCT01045486) for treating atopic dermatitis in infants who also have a cow's milk allergy. [1] The commercially available 'Duolac ATP' product is a powder containing four patented probiotic strains: *Lactobacillus casei* CBT-LC5, *Lactobacillus rhamnosus* CBT-LR5, *Lactobacillus plantarum* CBT-LP3, and *Bifidobacterium lactis* CBT-BL3. [5] Probiotics are live microorganisms that are thought to improve atopic dermatitis by beneficially modulating the gut microbiome and the host's immune system. [11, 15] The ATP component may function as an additional energy source or a signaling molecule. [4] Duolac products feature a patented dual-coating technology designed to protect the live bacteria from stomach acid, ensuring their delivery to the intestines. [17, 19]
- Brand names
- Duolac ATPDuolac
- Other names
- ATP mixed probiotics
Beyond the preview
Go deeper on Duolac ATP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duolac ATP.